Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer

Anlotinib can overcome acquired resistance to EGFR‐TKIs via FGFR1 signaling in non‐small cell lung cancer without harboring EGFR T790M mutation

(2020) Zengzhi Lian et al.   Thoracic Cancer

Acquired resistance to EGFR TKIs mediated by TGF-beta1/integrin beta3 signaling in EGFR-mutant lung cancer

(2019) Caiyun Wang et al.   MOLECULAR CANCER THERAPEUTICS

Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer

(2019) Xinwen Wang et al.   ONCOLOGY RESEARCH

Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3

(2018) Jinnan Yue et al.   ONCOGENE

Inhibiting Integrin β8 to Differentiate and Radiosensitize Glioblastoma-initiating Cells

(2018) Laure Malric et al.   MOLECULAR CANCER RESEARCH

EGFR mutation analysis for prospective patient selection in AURA3 phase III trial of osimertinib versus platinum-pemetrexed in patients with EGFR T790M-positive advanced non-small-cell lung cancer

(2018) Thomas John et al.   LUNG CANCER

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial

(2017) Yi-Long Wu et al.   LANCET ONCOLOGY

Exploring the Role of RGD-Recognizing Integrins in Cancer

(2017) Markus Nieberler et al.   Cancers

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

(2016) Nan Zhang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

FAK signaling in human cancer as a target for therapeutics

(2015) Brian Y. Lee et al.   PHARMACOLOGY & THERAPEUTICS

Expression of Small Integrin-Binding LIgand N-linked Glycoproteins (SIBLINGs) in the reparative dentin of rat molars

(2014) Xiaohua Xie et al.   DENTAL TRAUMATOLOGY

AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

(2014) D. A. E. Cross et al.   Cancer Discovery

Erlotinib Resistance in Lung Cancer Cells Mediated by Integrin  1/Src/Akt-Driven Bypass Signaling

(2013) R. Kanda et al.   CANCER RESEARCH

Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers

(2013) H. A. Yu et al.   CLINICAL CANCER RESEARCH

Symptom Control and Quality of Life in LUX-Lung 3: A Phase III Study of Afatinib or Cisplatin/Pemetrexed in Patients With Advanced Lung Adenocarcinoma WithEGFRMutations

(2013) James Chih-Hsin Yang et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma WithEGFRMutations

(2013) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Integrative Analyses Identify Osteopontin, LAMB3 and ITGB1 as Critical Pro-Metastatic Genes for Lung Cancer

(2013) Xiao-Min Wang et al.   PLoS One

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

HER2 Amplification: A Potential Mechanism of Acquired Resistance to EGFR Inhibition in EGFR -Mutant Lung Cancers That Lack the Second-Site EGFR T790M Mutation

(2012) Ken Takezawa et al.   Cancer Discovery

Cooperation Between Integrins and Growth Factor Receptors in Signaling and Endocytosis

(2011) Johanna Ivaska et al.   Annual Review of Cell and Developmental Biology

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

(2011) L. V. Sequist et al.   Science Translational Medicine

Anti- v Integrin Monoclonal Antibody Intetumumab Enhances the Efficacy of Radiation Therapy and Reduces Metastasis of Human Cancer Xenografts in Nude Rats

(2010) S. Ning et al.   CANCER RESEARCH

Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs

(2010) Jin-Haeng Chung et al.   LUNG CANCER

Secreted phosphoprotein 1 binds integrins to initiate multiple cell signaling pathways, including FRAP1/mTOR, to support attachment and force-generated migration of trophectoderm cells

(2010) Jinyoung Kim et al.   MATRIX BIOLOGY

Secreted Phosphoprotein 1 (SPP1, Osteopontin) Binds to Integrin Alphavbeta6 on Porcine Trophectoderm Cells and Integrin Alphavbeta3 on Uterine Luminal Epithelial Cells, and Promotes Trophectoderm Cell Adhesion and Migration1

(2009) David W. Erikson et al.   BIOLOGY OF REPRODUCTION

Down-regulation of αv integrin by retroviral delivery of small interfering RNA reduces multicellular resistance of HT29

(2009) Jian-ming He et al.   CANCER LETTERS

Integrins

(2009) Malgorzata Barczyk et al.   CELL AND TISSUE RESEARCH

Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status

(2009) Takamitsu Onitsuka et al.   LUNG CANCER